期刊文献+

208例肺栓塞的临床分析 被引量:3

Clinical Analysis of 208 Cases of Pulmonary Embolism
下载PDF
导出
摘要 目的回顾性分析肺栓塞病例的临床特点、诊断和治疗方法,减少漏诊、误诊,提高对肺栓塞患者的诊断率和治愈率。方法对2009年1月至2013年9月入住山西省人民医院的208例肺栓塞患者的相关危险因素、临床表现、辅助检查结果及治疗方法进行回顾性分析。结果 1肺栓塞患者临床表现多样,主要有呼吸困难、咳嗽、胸憋、胸痛和下肢肿胀。2肺栓塞的主要相关危险因素依次为深静脉血栓形成、高血压、吸烟和心功能不全。3常规检查项目中D-二聚体测定可作为筛查肺栓塞的敏感但非特异性指标。4溶栓序贯抗凝治疗与单纯抗凝治疗的治愈率比较二者差异有统计学意义,总有效率差异无统计学意义。结论肺栓塞临床表现及常规检查缺乏特异性,对疑诊患者应综合考虑,提高确诊率,积极治疗。 Objective To retrospectively analyze the clinical features,diagnosis and therapy of pulmonary embolism for reduction of misdiagnosis and missed diagnosis, and for improving the cure rate. Methods The data of related risk factors, clinical manifestation, auxiliary examination results and treatment of 208 patients with pulmonary embolism in Shanxi Province people's hospital were summarized. Results 1Pulmonary embolism in patients with clinical manifestations of diversity, mainly include dyspnea, cough, chest suppress, chest pain and swelling of lower limbs. 2The main risk factors related to pulmonary embolism are deep vein thrombosis, high blood pressure, smoking and cardiac insufficiency. 3Routine inspection project D-dimer determination can be used as screening sensitive but not specific indicator of pulmonary embolism. 4Thrombolysis sequential anticoagulation compared with pure anticoagulant therapy cure rate was statistically significant difference in, there was no statistically significant difference in total effective rate. Conclusions clinical manifestation of pulmonary embolism and routine inspection lack of specificity, and should be considered in patients with suspected diagnosis, increase the rate of diagnosis, treat actively.
出处 《中国医药指南》 2015年第10期4-5,共2页 Guide of China Medicine
关键词 肺栓塞 危险因素 治疗 Pulmonary embolism Risk factors Therapy
  • 相关文献

参考文献9

二级参考文献42

  • 1Miller GA, Sutton GC, Kerr IH, et al. Comparison of streptokinase and beparin in treatment of isolated acute massive pulmonary embolism. Br Med J, 1971,2: 681-684.
  • 2赵一举 程显声 刘蕴忠.急性肺栓塞尿激酶溶栓成功一例[J].中华心血管病杂志,1992,:15-15.
  • 3Lankeit M, Konstantinides S. Thrombolysis for pulmonary embolism: Past, present and future. Thromb Haemost, 2010, 103 : 877-883.
  • 4Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism. Circulation, 2010, 122: 1124-1129.
  • 5Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation, 2011, 123: 1788-1830.
  • 6Torbicki A, Pettier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2008, 29: 2276-2315.
  • 7Hyers TH, Agnelli G, Hull RD, et al. Antithrombotie therapy for venous thromboembolic disease. Chest, 2001, 119: 176S-193S.
  • 8Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. Chest, 1992, 101: 183S-185S.
  • 9Meneveau N, Sehiele F, Vuillemenot A, et al. Streptokinase vs aheplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J, 1997, 18: 1141-1148.
  • 10Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of two-hour regimen of streptokinase versus aheplase in acute massive pulmonary embolism : immediate clinical and hemodynamic outcome and one-year follow-up J Am Coll Cardiol, 1998, 31: 1057-1063.

共引文献2063

同被引文献19

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部